After the firing of FBI Director James Comey just under a month ago, President Trump had promised a swift filling of the vacancy. While many had expected an appointment would have been made by now, several of the individuals who were interviewed by the administration ended up taking their names out of consideration.
After what we were told to be a chaotic search to fill Comey’s position, President Trump, in a Tweet just moments ago announced the next Director of the FBI:
“I will be nominating Christopher A. Wray, a man of impeccable credentials, to be the new Director of the FBI. Details to follow.”
Wray, 50 graduated from Yale University in 1989 and received his law degree from Yale Law School in 1992. From there he went on to be clerk for Judge J. Michael Luttig of the U.S. Court of Appeals for the Fourth Circuit before launching his private practice in 1993. In 2003, Mr. Wray was nominated by President George W. Bush as the Assistant Attorney General in charge of the Criminal Division, which he served at until 2005. Since 2005 he has been working at his private practice as a litigation attorney at King and Spalding, where he has quite notably represented New Jersey Governor Chris Christie in the BridgeGate scandal.
This appointment is somewhat surprising as Wray certainly isn’t even close to being a household name, and I’m sure political pundits on both sides of the isle will now have to do some digging in order to figure out if there are any possible conflicts of interest in this appointment. Below are some of his accomplishments throughout his career, according to King and Spalding Law:
- Two different Fortune 100 financial institutions in a number of parallel investigations by the Department of Justice and other agencies, such as the SEC, IRS and OCC, as well as parallel class action litigation.
- Several of the world’s leading pharmaceutical companies in investigations into off-label promotion issues by the Department of Justice and multiple U.S. Attorneys’ Offices, the FDA, HHS-OIG, Congress, and various state Attorneys General, as well as parallel False Claims Act qui tam litigation.
- A Fortune 100 healthcare company in multiple federal and state regulatory investigations around the country.
- A special committee of the board of directors of a leading technology company in conducting an independent investigation of stock options issues.
- A Fortune 100 pharmacy benefits company in parallel investigations by the Department of Justice and SEC into stock options issues.
- A leading telecommunications company in parallel Department of Justice, SEC, IRS, and Department of Labor investigations into stock options practices.
- A leading global financial institution in parallel investigations by the Department of Justice, Manhattan District Attorney’s Office, Treasury Department’s Office of Foreign Assets Control (OFAC), New York Federal Reserve Bank, and various domestic and foreign regulatory agencies.
- A leading global financial institution in parallel investigations by the Department of Justice, IRS, SEC, New York Federal Reserve Bank, New York Department of Financial Services (DFS), Congress and foreign regulatory agencies.
- One of the largest global medical device manufacturers in parallel Department of Justice and SEC investigations of Foreign Corrupt Practices Act issues.
- A Fortune 100 transportation company in conducting internal investigations of Foreign Corrupt Practices Act issues voluntarily disclosed to the Department of Justice and SEC.
- Two different Fortune 250 energy companies in conducting internal investigations of Foreign Corrupt Practices Act issues.
- A leading defense contractor in qui tam litigation under the False Claims Act.
- The audit committee of the board of directors of a Fortune 250 technology company in conducting an independent investigation of revenue recognition and corporate governance issues.
- The Governor of New Jersey in connection with investigations relating to the George Washington Bridge toll lane closings.
- Court-appointment as a Special Master to help the court resolve a discovery dispute between the Department of Justice and a major healthcare company in False Claims Act litigation.
- Appointment by the World Bank as the compliance consultant under a settlement with a leading global technology company.